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Abstract
Background: We previously found that r-hu-IFNγ exerts a potent anti-tumor effect on human
nasopharyngeal carcinoma xenografts in vivo. Considering the fact that the clinical use of
recombinant IFNγ is limited by its short half-life and systemic side effects, we developed a
recombinant adenovirus, Ad-IFNγ.
Methods: Dynamic distribution of the adenovirus vector and expression of IFNγ were evaluated
by Q-PCR and ELISA after intratumoral administration of Ad-IFNγ into CNE-2 xenografts.
Results: Ad-IFNγ DNA was mainly enriched in tumors where the Ad-IFNγ DNA was injected (P
< 0.05, compared to blood or parenchymal organs), as well as in livers (P < 0.05). Concentrations
of Ad-IFNγ DNA in other organs and blood were very low. Intratumoral Ad-IFNγ DNA decreased
sharply at high concentrations (9 × 105 copies/μg tissue DNA), and slowly at lower concentrations
(1.7–2.9 × 105 copies/μg tissue DNA). IFNγ was detected in the tumors and parenchymal organs.
The concentration of IFNγ was highest in the tumor (P < 0.05), followed by the liver and kidney (P
< 0.05). High-level intratumoral expression of IFNγ was maintained for at least 7 days, rapidly
peaking on day 3 after injection of Ad-IFNγ DNA.
Conclusion:  An IFNγ gene delivered by an adenoviral vector achieved high and consistent
intratumoral expression. Disseminated Ad-IFNγ DNA and the transgene product were mainly
enriched in the liver.
Background
IFNγ, a homodimeric cytokine produced by T lym-
phocytes and natural killer cells, belongs to a family of
glycoproteins that have antiviral, immunomodulatory,
and anti-proliferative effects. The anti-tumor activities of
IFNγ have been shown in various kinds of tumors, such as
lymphomas, melanomas, and metastatic renal cell carci-
nomas [1-4]. Nasopharyngeal carcinoma (NPC) is a
malignant disease of the head/neck region that is endemic
in Southeast Asia [5]. We have reported that r-hu-IFNγ
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treatment exerts anti-proliferative effects in vitro on NPC
cells, and leads to a profound anti-tumor effect in vivo [6].
However, although IFNγ has shown some promise in pre-
clinical and clinical anticancer studies, it possesses prop-
erties that limit its clinical use.
High serum concentrations of IFNγ yield significant side
effects and toxicities. These side effects include fever,
fatigue, nausea, vomiting, neurotoxicity, and leukopenia.
In addition, IFNγ has a short half-life of elimination,
whether given intravenously, subcutaneously, or intra-
muscularly, and thus requires relatively frequent readmin-
istration. These limitations have prompted the
investigation of alternate modes of delivering this
cytokine to achieve better therapeutic outcomes while
minimizing toxicity [1]. Studies have revealed that the
most efficient and least toxic delivery system for IFNγ is a
localized, sustained release dosage form [1,3,4]. There-
fore, gene therapy with intratumorally injected recom-
binant adenoviral vectors is a promising approach
because it offers the potential to achieve consistent thera-
peutic gene expression in the tumor [3,4].
In the present study, we developed a recombinant adeno-
virus, Ad-IFNγ, encoding human interferon gamma. To
determine whether intratumoral administration of Ad-
IFNγ could achieve localized sustained expression of IFNγ,
we sought to characterize the biodistribution of the aden-
oviral vector and transgene expression in the tumor,
blood, liver, kidney, heart, brain, spleen, and lung at days
1, 2, 3, 5, 7, 14, and 21 after injection. Results indicated
that the IFNγ gene delivered by adenoviral vector achieved
high intratumoral expression, lasting for at least 7 days
after injection of Ad-IFNγ. Disseminated Ad-IFNγ DNA
and the transgene product were mainly enriched in the
liver.
Methods
Adenoviral vectors
E1-deleted, replication-deficient adenoviral vectors based
on human adenovirus serotype Ad5 were used to produce
the non-replicating adenovirus, Ad-IFNγ, encoding
human interferon gamma [7]. The cDNA for IFNγ was
inserted into the E1 region of the adenoviral genome with
transgene expression driven by the cytomegalovirus
(CMV) promoter. Adenoviruses were propagated in 293
cells (American Type Culture Collection, Manassas, VA,
USA), harvested at 48 h after infection, and purified by
cesium chloride gradient centrifugation according to a
standard protocol [8], resulting in a particle:pfu ratio of
100:3.32. The viral vectors were stored at -80°C in virus
preservation solution (10% glycerol, 0.585% NaCl,
0.02% MgCl2·H2O, 0.01 M Tris-HCl, pH 8.4) at a concen-
tration of 1 × 1012 VP/ml.
Animals
Female BALB/c nude mice (4–6 weeks old) were obtained
from the Experimental Animal Center (Sun Yat-sen Uni-
versity, Guangzhou, China) and maintained in a specific
pathogen-free (SPF) environment. After 1 week of adapta-
tion, mice were inoculated subcutaneously in the scapular
region with 2 × 106 CNE-2 cells to generate tumors for
subsequent experiments. When tumors reached 5–8 mm
in diameter, mice were randomly assigned to groups (3
mice for each time point). Ad-IFNγ (diluted with 0.9%
NaCl to 100 μl) or vehicle was delivered into the center of
the tumor via a single injection with a 30-gauge needle.
The dose used per injection was 1 × 1010 VP/tumor. Sam-
ples of blood, tumor, heart, liver, spleen, lung, kidney,
and brain were harvested at the indicated time points after
virus injection, and stored in aliquots at -80°C for analy-
sis. All the animal experiments were conducted in accord-
ance with "Guidelines for the Welfare of Animals in
Experimental Neoplasia".
Quantitative analysis of adenovirus distribution
Tissue samples (about 50 mg for tissue) were immersed in
liquid nitrogen and ground into fine tissue powder in a
mortar. Viral DNA was isolated from the tissue powder
and whole blood (about 100 μl for blood) using a Total
DNA Extraction Kit (TIANGEN, Beijing, China).
Quantitative PCR
Adenovirus copies in the samples were measured by
hexon DNA PCR [9]. Primer and probe sequences were:
hexon forward primer: 5'-CTTCGATGATGCCGCAGTG-3';
hexon reverse primer: 5'-GGGCTCAGGTACTCCGAGG-3';
hexon probe: 5'-FAM-TTACATGCACATCTCGGGCCAG-
GAC-TAMRA-3'. Amplification was performed in a 50 μl
reaction volume under the following conditions: 10 ng of
sample DNA, 1× Taqman Universal PCR Master Mix, 600
nM forward primer, 900 nM reverse primer, and 100 nM
hexon probe. Thermal cycling conditions were: 2 min of
incubation at 50°C, 10 min at 95°C, followed by 35
cycles of successive incubations at 95°C for 15 sec and
60°C for 1 min [9]. Quantification of adenovirus copy
number was performed using a standard curve consisting
of dilutions of adenovirus DNA from 1,500,000 to 15
copies in 10 ng of cellular genomic DNA.
Quantitative analysis of IFN  distribution
After being immersed in liquid nitrogen and ground into
fine tissue powder in a mortar, tissue samples (about 50
mg) were ground with PBS containing Protease Inhibitor
Cocktail II (Upstate, Lake Placid, NY, USA). After centrif-
ugation, the supernatants were extracted and stored at -
80°C. IFNγ concentrations in the tumor, organ extracts,
and plasma samples (about 100 μl) were detected with a
human IFNγ ELISA kit (R&D Systems, Minneapolis, MN,
USA) according to the manufacturer's recommendations.BMC Cancer 2009, 9:55 http://www.biomedcentral.com/1471-2407/9/55
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Ad-IFNγ concentrations in the tumor, heart, liver, spleen, lung, kidney, brain, and blood at different time points after intratu- moral injection of Ad-IFNγ Figure 1
Ad-IFNγ concentrations in the tumor, heart, liver, spleen, lung, kidney, brain, and blood at different time 
points after intratumoral injection of Ad-IFNγ. The dose of injection was 1 × 1010 VP/tumor. Data represent mean ± SD 
of three mice. Representative results from two independent experiments are shown.BMC Cancer 2009, 9:55 http://www.biomedcentral.com/1471-2407/9/55
Page 4 of 7
(page number not for citation purposes)
The results were then converted to the concentrations of
IFNγ in the different tissues based on the sample volume
or weight. Sensitivity of the kit was up to 16 pg/ml.
Statistical Analysis
Results were evaluated using a t-test by SPSS 11.0 software
(SSPS Inc., Chicago, IL, USA). A P value < 0.05 was con-
sidered statistically significant.
Results
Systemic distribution of recombinant human IFN  
adenovirus
1 × 1010 VP of Ad-IFNγ was injected into CNE-2 tumors.
At the indicated time points post-injection, samples of
tumor, parenchymal organs, and blood were harvested.
To demonstrate adenovirus distribution, fluorescent real-
time quantitative PCR was used to quantify viral copies in
the samples.
Samples from tumor, heart, liver, spleen, lung, kidney,
brain, and blood on days 1, 2, 3, 5, 7, 14 and 21, were
tested for the amount of targeted DNA. The copy number
of the targeted DNA in samples was deduced according to
the standard curves. As shown in Fig. 1, Ad-IFNγ DNA was
detected in tumor, blood, and parenchymal organs. Ad-
IFNγ DNA was mainly enriched in tumors where the Ad-
IFNγ DNA was injected (P < 0.05, compared to blood or
parenchymal organs), then in livers (P < 0.05, compared
to blood or other parenchymal organs). Concentrations
of Ad-IFNγ DNA were very low in other organs and blood
(Fig. 1). Ad-IFNγ DNA persisted for at least 7 days in the
tumors. Intratumoral Ad-IFNγ DNA decreased sharply at
high concentrations (9 × 105 copies/μg tissue DNA), and
slowly at lower concentrations (1.7–2.9 × 105 copies/μg
tissue DNA) (Table 1). Ad-IFNγ DNA in livers also
decreased in a time-dependent manner and became unde-
tectable at day 14 after intratumoral administration
(Table 1).
Systemic distribution of human IFN  expressed by Ad-IFN
To evaluate the dynamic expression in vivo of the trans-
gene from the recombinant human IFNγ adenovirus, we
used ELISA to test the levels of IFNγ in samples collected
from tumor, heart, liver, spleen, lung, kidney, brain, and
blood on days 1, 2, 3, 5, 7, 14, and 21 post-injection of
Ad-IFNγ. IFNγ was detected in tumor and parenchymal
organs, while IFNγ was undetectable in blood (Fig. 2). The
concentration of IFNγ in tumor was highest (P < 0.05,
compared to blood or parenchymal organs), then in liver
and kidney (P < 0.05, compared to blood or other paren-
chymal organs). As shown in Fig. 2, intratumoral concen-
trations of IFNγ protein, in contrast to the amount of Ad-
IFNγ DNA, rose rapidly and peaked on day 3 after injec-
tion of Ad-IFNγ DNA, then decreased sharply. On day 14
and 21, only a minimal amount of IFNγ remained in the
tumor. Concentrations of IFNγ in the liver and kidney
peaked on day 5. On day 7, IFNγ in all tissues decreased
dramatically with the exception of maintained high-level
expression in the liver. While low levels of IFNγ were still
present in the liver on days 14 and 21, IFNγ in other
organs was almost undetectable.
Discussion
Nasopharyngeal carcinoma is a major malignant disease
of the head and neck region that is endemic to Southeast
Asia and the Mediterranean basin. NPC affects a predom-
inantly young population and the current treatment regi-
men of radiation therapy, even combined with cisplatin
chemotherapy, yields a 5-year survival rate of approxi-
mately 70%. Therefore, evaluation and development of
novel therapeutic approaches are critical [9-14]. We had
previously found that r-hu-IFNγ has direct anti-prolifera-
tive effects on all NPC cell lines tested (CNE-1, CNE-2 and
C666-1) [6]. Moreover, r-hu-IFNγ potently inhibits the
growth of CNE-2 and C666-1 xenografts in vivo [6]. Thus,
our study revealed that r-hu-IFNγ treatment is a promising
novel approach for the treatment of NPC. However, the
clinical application of recombinant IFNγ is limited by the
short half-life and the systemic side effects experienced by
patients. Therefore, continuous localized release of IFNγ is
a desirable goal. To overcome these difficulties, we devel-
oped a recombinant adenovirus, Ad-IFNγ. Our results sug-
gested that high and sustained expression of IFNγ could
be achieved in CNE-2 xenografts, after intratumoral injec-
Table 1: Adenovirus copies in tumors and livers were measured by hexon DNA PCR.
tumor (copies/μg tissue DNA) liver (copies/μg tissue DNA)
day 1 897927.2 ± 188201.2 206274.7 ± 67269.5
day 2 645995.1 ± 76137.4 168531.6 ± 46526.4
day 3 289441.2 ± 75017.3 109217.2 ± 5478.3
day 5 197677.1 ± 220320.1 90712.8 ± 68176.5
day 7 169882.6 ± 69067.4 11465.8 ± 2383.5
day 14 0 0
day 21 0 0
The dose of injection was 1 × 1010 VP/tumor. Data represent mean ± SD of three mice. Representative results from two independent experiments 
are shown.BMC Cancer 2009, 9:55 http://www.biomedcentral.com/1471-2407/9/55
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Human IFNγ concentrations in the tumor, heart, liver, spleen, lung, kidney, and brain at different time points after intratumoral  injection of Ad-IFNγ Figure 2
Human IFNγ concentrations in the tumor, heart, liver, spleen, lung, kidney, and brain at different time points 
after intratumoral injection of Ad-IFNγ. The dose of injection was 1 × 1010 VP/tumor. Data represent mean ± SD of 
three mice. Representative results from two independent experiments are shown.BMC Cancer 2009, 9:55 http://www.biomedcentral.com/1471-2407/9/55
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tion of Ad-IFNγ (Fig. 2). Consistent with the anti-tumor
effects of r-hu-IFNγ, Ad-IFNγ produced a significant dose-
dependent inhibition of tumor growth in CNE-2 models.
Intratumoral administration of Ad-IFNγ at doses of 1 ×
109 and 5 × 108 pfu/week for three weeks led to inhibi-
tion rates of 67.9% and 58.64%, respectively [see Addi-
tional file 1, Zhu YH, et al., unpublished data].
Intratumoral injection is an advantageous method for
local viral gene delivery [15,16]. Researchers often assume
that viral vectors and transgene expression are confined to
solid tumors after the infusion, thereby causing minimal
toxicity in normal tissues. However, the dissemination of
the viral vector and its encoded gene product could be a
serious impediment for vectors that encode cytokine
genes, such as IFNγ, that are not only expressed in situ, but
also secreted into the system and have considerable nor-
mal tissue toxicity [17-20]. Therefore, we investigated
transgene expression in the blood and major organs in
this study.
We found that there was potential dissemination of viral
DNA and transgene product into parenchymal organs. A
significant amount of IFNγ was detected in the liver and
kidney, which indicated that the clearance of IFNγ in vivo
is through hepatic metabolism and glomerular filtration.
Our results also suggested that most of the disseminated
viral DNA was enriched in the liver, which is consistent
with reports of efficient uptake of adenovirus by the liver.
There was a minimal amount of viral DNA in the blood.
One possible explanation for this is that the number of
infectious viruses present in the blood was significantly
reduced through rapid uptake of the virus by Kupffer cells
in the liver [21,22].
Studies have revealed that dissemination of transgene
products in normal organs, such as in the liver, may
exceed normal tissue tolerance if the products are highly
toxic [19]. Toxicological studies conducted in this lab
have indicated that intratumoral injection of Ad-IFNγ
doesn't induce significant toxic effects in mice [unpub-
lished data]. Therefore, adenovirus-mediated intratu-
moral delivery of the IFNγ gene is a promising approach
because it achieves high and sustained local IFNγ expres-
sion in the tumor.
Conclusion
Adenovirus-mediated intratumoral delivery of the IFNγ
gene is a promising approach because it achieves high and
sustained local IFNγ expression in the tumor. Dissemi-
nated Ad-IFNγ DNA and the transgene product were
mainly enriched in the liver.
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